Shares of Johnson & Johnson JNJ, -2.28% fell 2.4% early Tuesday, to pace the Dow Jones Industrial Average’s DJIA, -0.49% premarket decliners, after health regulators put a pause on the company’s COVID-19 vaccine following “extremely rare” cases of blood clots. The stock’s implied price decline would shave about 25 points off the Dow’s price, while Dow futures YM00, -0.58% shed 96 points, or 0.3%. Currently 21 of the Dow’s 30 components are declining ahead of the open. J&J’s stock has edged up 2.7% year to date through Monday, while the Dow has climbed 10.3%.
View Article Origin Here
